Do we need a new strategy to treat metastatic breast cancer? Joseph R. BertinoOwen A. O’Connor Invited Commentary Pages: 85 - 87
Integration of chemotherapy into the definitive management of squamous cell head and neck cancer David J. Adelstein Clinical Trials Review Pages: 97 - 98
Altered fractionation in the treatment of head and neck cancer Kenneth S. HuLouis B. Harrison OriginalPaper Pages: 110 - 123
Quality-of-life issues in head and neck cancer Ehab HannaAllen C. Sherman OriginalPaper Pages: 124 - 128
Clinical implications of biomarkers in head and neck cancer Wayne M. Koch OriginalPaper Pages: 129 - 137
Combined modality therapy for esophageal cancer Ziv GamlielMark J. Krasna OriginalPaper Pages: 149 - 154
Novel chemotherapy agents for colorectal cancer: Oral fluoropyrimidines, oxaliplatin, and raltitrexed Melanie E. RoycePaulo M. HoffRichard Padzur OriginalPaper Pages: 161 - 167
The role of carcinoembryonic antigen monitoring in management of colorectal cancer Mary F. MulcahyAl B. Benson III OriginalPaper Pages: 168 - 172
Cyclooxygenase-2 as a target for prevention of colorectal cancer Monica M. Bertagnolli OriginalPaper Pages: 173 - 178